The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US

被引：0
|
作者：
Buthainah Ghanem
Lu Shi
机构：
[1] Chapman University,Department of Pharmaceutical Economics and Policy, School of Pharmacy
[2] Oregon State University,College of Public Health and Human Sciences
来源：
BioDrugs | 2022年 / 36卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：773 / 780
页数：7
相关论文
共 50 条
  • [1] The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US
    Ghanem, Buthainah
    Shi, Lu
    BIODRUGS, 2022, 36 (06) : 773 - 780
  • [2] A Comparison of Standard of Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel CAR T-cell Therapy in Relapsed or Refractory Multiple Myeloma
    Hansen, Doris
    Peres, Lauren
    Dima, Danai
    Richards, Alicia
    Shune, Leyla
    Afrough, Aimaz
    Midha, Shonali
    Dhakal, Binod
    Kocoglu, Mehmet H.
    Ferreri, Christopher
    Davis, James
    Herr, Megan
    Forsberg, Peter
    Janakiram, Murali
    Reshef, Ran
    Sborov, Douglas W.
    Khouri, Jack
    Richard, Shambavi
    Martin, Thomas
    Lin, Yi
    Patel, Krina
    Sidana, Surbhi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S5 - S5
  • [3] Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study
    Merz, Maximilian
    Albici, Anca-Maria
    von Tresckow, Bastian
    Rathje, Kristin
    Fenk, Roland
    Holderried, Tobias
    Mueller, Fabian
    Tovar, Natalia
    Oliver-Caldes, Aina
    Vucinic, Vladan
    Kharboutli, Soraya
    Baermann, Ben-Niklas
    Ayuk, Francis
    Platzbecker, Uwe
    Stoelzel, Friedrich
    Schub, Nathalie
    Schmitz, Friederike
    Fandrei, David
    Born, Patrick
    Khandanpour, Cyrus
    Hanoun, Christine
    Hoerster, Keven
    Teichert, Marcel
    Jeker, Barbara
    Hoffmann, Michele
    Kroeger, Nicolaus
    de Larrea, Carlos Fernandez
    Pabst, Thomas
    Gagelmann, Nico
    HEMASPHERE, 2025, 9 (01):
  • [4] Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie's choice for patients with relapsed refractory multiple myeloma
    Davis, James
    McGann, Mary
    Shockley, Abigail
    Hashmi, Hamza
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (06) : 473 - 475
  • [5] Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities-a Multicenter Study
    Chang, Darryl
    Habib, Alma
    Uegel, Andrew
    Struble, Emily
    Shaikh, Hira
    Strouse, Christopher
    Green, Kimberly M.
    Mushtaq, Muhammad Umair
    Mahmoudjafari, Zahra
    Hashmi, Hamza
    Mcguirk, Joseph P.
    Khan, Abdullah Mohammad
    Abdallah, Al-Ola
    Ahmed, Nausheen
    Atrash, Shebli
    Bhutani, Manisha
    BLOOD, 2024, 144 : 2404 - 2405
  • [6] In vivo expansion patterns of anti-BCMA CAR T-cell in relapsed/refractory multiple myeloma: Comparative immunomonitoring of idecabtagene vicleucel and ciltacabtagene autoleucel
    Kocoglu, Mehmet
    Rapoport, Aaron P.
    Gebru, Etse
    Omili, Destiny
    Yamoah, Daniel
    Mulatu, Rediet
    Yared, Jean
    Hardy, Nancy M.
    Kallen, Michael
    Badros, Ashraf Z.
    Atanackovic, Djordje
    CANCER RESEARCH, 2024, 84 (06)
  • [7] A Real-World Comparison of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel CAR-T Therapy: A Single Center Experience for Relapsed/ Refractory Multiple Myeloma
    Gill, Sarvarinder Kaur
    Biran, Noa
    Phull, Pooja
    Vesole, David H.
    Siegel, David S.
    Parmar, Harsh
    BLOOD, 2023, 142
  • [8] Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US
    Buthainah Ghanem
    Lu Shi
    Clinical Drug Investigation, 2022, 42 : 1085 - 1092
  • [9] Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US
    Ghanem, Buthainah
    Shi, Lu
    CLINICAL DRUG INVESTIGATION, 2022, 42 (12) : 1085 - 1092
  • [10] Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma
    Anderson, Larry D., Jr.
    FUTURE ONCOLOGY, 2021, 18 (03) : 277 - 289
12345